Low Density Lipoprotein-Containing Circulating Immune Complexes: Role in Atherosclerosis and Diagnostic Value

Igor A. Sobenin, 1,2 Jukka T. Salonen, 3,4 Andrey V. Zhelankin, 1,2 Alexandra A. Melnichenko, 2 Jari Kaikkonen, 5 Yuri V. Bobryshev, 2,6,7 and Alexander N. Orekhov 2,8

1 Russian Cardiology Research and Production Complex, Moscow, Russia
2 Institute of General Pathology and Pathophysiology, Moscow, Russia
3 Hjelt Institute, University of Helsinki, Helsinki, Finland
4 MAS-Metabolic Analytical Services Oy, Helsinki, Finland
5 The Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland
6 Faculty of Medicine, School of Medical Sciences, University of New South Wales, Kensington, Sydney, NSW 2052, Australia
7 School of Medicine, University of Western Sydney, Campbelltown, NSW, Australia
8 Institute for Atherosclerosis Research, Skolkovo Innovation Center, Moscow, Russia

Correspondence should be addressed to Yuri V. Bobryshev; y.bobryshev@unsw.edu.au

Received 18 March 2014; Revised 29 May 2014; Accepted 6 June 2014; Published 18 June 2014

Academic Editor: Tin Soe Kyaw

Copyright © 2014 Igor A. Sobenin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

It has been suggested that low density lipoprotein-containing circulating immune complexes (LDL-CIC) play a role in atherogenesis and are involved in the formation of early atherosclerotic lesion. These complexes, as well as anti-LDL autoantibodies, have been found in the blood and in the atherosclerotic lesions of patients with different cardiovascular diseases, as well as in the blood of animals with experimental atherosclerosis. It can be suggested that the presence of anti-LDL antibodies in the blood is a result of immune response induced by lipoprotein modification. LDL-CIC differs from native LDL in many aspects. It has much lower sialic acid content, smaller diameter, and higher density and is more electronegative than native LDL. Fraction of LDL-CICs is fundamental to the serum atherogenicity manifested at the cellular level. LDL-CIC, unlike native LDL, is able to induce intracellular accumulation of neutral lipids, especially esterified cholesterol, in cells cultured from uninvolved human aortic intima and in macrophage cultures. After removal of LDL-CIC, the CHD patient’s sera lose their atherogenic properties. Titer of LDL-CIC in blood serum significantly correlates with progression of atherosclerosis in human in vivo and has the highest diagnostic value among other measured serum lipid parameters. Elevated CIC-cholesterol might well be a possible risk factor of coronary atherosclerosis.

1. Introduction

Widely spread clinical manifestations of atherosclerosis such as coronary heart disease (CHD), cerebrovascular stroke, renovascular hypertension, and violation of the lower limbs vascular permeability, are the result of formation of advanced atherosclerotic lesions in a vascular wall. A trigger mechanism for the development of atherosclerotic lesions is an intracellular lipid deposition and subsequent foam cell formation with excessive production of connective tissue matrix components and, possibly, cellular proliferation and inflammatory reactions [1, 2]. Atherosclerosis can be generally described as an excessive fibrofatty, proliferative, inflammatory response to damage of the artery wall, involving several cell types, such as smooth muscle cells, monocyte-derived macrophages, lymphocytes, and platelets [3]. During the last three decades, the autoimmune hypothesis of atherosclerosis was developed and the evidence for an important role for autoantibodies against modified low density lipoprotein (LDL) and LDL-containing circulating immune complexes (LDL-CIC) in atherogenesis has been accumulated. Immunological factors appear to contribute to the development of atherosclerosis as many other factors including alterations in plasma lipid and lipoprotein levels, platelet function,
clotting factors, arterial smooth muscle cell metabolism, and 
blood pressure regulation. In a number of recent studies it has 
been suggested that the presence of LDL-CIC in the 
blood promotes the onset and development of atherosclerotic 
lesions in the vessel wall. It has been demonstrated that 
modified LDL and especially LDL-CIC act as the primary 
agents responsible for excessive cholesterol accumulation in 
vascular cells [4–9]. The atherogenic properties of LDL-
containing immune complexes suggest them as a candidate 
marker for atherosclerosis.

2. LDL-CIC and Its Physicochemical 
Characteristics

Anti-LDL autoantibodies were first detected in the blood 
of patients with hyperlipidemia accompanied by myeloma 
or/and ischemic heart disease [10]. In 1965, Beaumont [11] 
described a situation in which hyperlipidemia, xanthomato-
sis, and atherosclerosis were apparently associated with anti-
ß-lipoprotein antibodies. The antibodies against lipoproteins 
or LDL-binding factors were found in the blood of patients 
suffering from various vascular diseases as well as in healthy 
subjects [12]. Bauer et al. established that immunoglobulins 
are the major LDL-binding proteins in human plasma [13]. The 
emergence of anti-LDL autoantibodies in the blood 
implies that lipoproteins can be regarded as autoantigens. The 
high immunogenicity and ability of homologous chemically 
modified LDL to generate antibodies have been demonstrated 
[14]. The discovery of autoantibodies in modified LDL in 
the blood of patients therefore seems natural. Autoantibodies 
against glycosylated LDL were detected in the blood of 
patients with diabetes mellitus [15]. Autoantibodies specific 
for malondialdehyde-modified LDL have been found in the 
blood of healthy subjects and patients with coronary artery 
disease, as well as in the blood of experimental animals [16]. 
Deposits of the immune complex components were found 
in vascular atherosclerotic lesions [17–19]. Autoantibodies of 
immunoglobulin G class against modified LDL were detected 
in the blood of patients with angiographically assessed 
coronary atherosclerosis [2, 12, 20–23]. In healthy subjects, 
the level of anti-LDL autoantibodies was considerably lower 
than that in atherosclerotic patients [2]. These autoantibodies 
hibit a high affinity for desialylated LDL (neuraminidase-
treated LDL) and for malondialdehyde-modified LDL. They 
have a lower affinity for native, oxidized, glycosylated, and 
acylated LDL, as well as for LDL, which has undergone 
other chemical modifications. The higher affinity of autoanti-
obides for modified LDL compared with native LDL suggests 
that the antibodies are produced in vivo in response to the 
appearance of modified LDL in the blood [24, 25].

Antibodies against LDL modified with malondialdehyde 
(MDA) have been detected in the blood of animals with 
experimental atherosclerosis and in atherosclerotic lesions 
in humans [25–28]. Even though elevated levels of oxidized 
lipids, such as MDA and F₂-isoprostanes, have been found 
in the blood of subjects with CHD [29, 30], there is some 
evidence that oxidized lipids do not accumulate in noticeable 
amounts in human LDL since high density lipoproteins seem 
to detoxify and/or transfer them from the circulation to 
the liver [31]. On the other hand, electronegative LDL [32], 
small/dense LDL [33], and desialylated LDL differing from 
native LDL by lowered sialic acid content [2, 34, 35] were 
found in the blood of patients with coronary atherosclerosis.

It can be suggested that the presence of anti-LDL antibod-
ies in the blood is a result of immune response induced by 
lipoprotein modification. Tertov et al. [36] isolated circulating 
immune complexes from blood serum using polyethylene 
glycol 6000 and have found that LDL-CIC differs from 
native LDL in many aspects (Table 1). Specifically, it has 
low sialic acid content; that is, it is desialylated LDL. The 
nearal lipid and phospholipid contents of LDL-CIC are 
considerably lower than those in native LDL. Particles of 
LDL-CIC have a smaller diameter and higher density. The 
higher electrophoretic mobility shows that LDL-CIC is more 
electronnegative than native LDL. Finally, LDL-CIC, unlike 
native LDL, is able to induce intracellular accumulation 
of neutral lipids, especially esterified cholesterol, in cells 
cultured from uninvolved human aortic intima. Thus, it was 
shown that LDL-CIC is quite similar to the multiple-modified 
(desialylated) LDL described earlier [37–39]. There was a 
strong correlation between the LDL content in circulating 
immune complexes and blood concentration of desialylated 
LDL but not of total LDL. This suggests that predominantly 
desialylated LDL forms complex with autoantibodies and 
proves that the affinity of circulating anti-LDL autoanti-
bodies is higher for desialylated LDL than for native LDL 
[36]. Moreover, anti-LDL autoantibodies bind much more 
effectively with LDL of patients having a high percentage of 
desialylated LDL than with LDL of healthy subjects having 
a low content of desialylated LDL [40]. Desialylated LDL 
has certain modifications that could stimulate the immune 
response: alterations in carbohydrate composition and in the 
tertiary structure of apo B, modification of lysine amino 
groups, and aggregation of lipoprotein particles [38, 39].

3. Atherogenicity of LDL-CIC

The investigation of proatherogenic role of LDL-CIC has 
started long ago, and it seems relevant to look into historical 
perspective to revive the interest in this topic. The first experi-
mental data on the effect of LDL and anti-LDL autoantibodies
on cell metabolism were reported by Beaumont's group as far as in 1979 [41]. It was found that incubating cultured fibroblasts with LDL, forming immune complexes with antibodies, facilitated intracellular cholesterol accumulation.

Klimov et al. have demonstrated that mouse macrophages cultured in the presence of immune complexes containing LDL and rabbit anti-human LDL antibodies demonstrated an increased uptake of LDL [42]. They have also shown that incubation of human peritoneal macrophages with autologous LDL-containing immune complexes causes transformation of macrophages into foam cells [38].

Griffith et al. [43] have found that human macrophages incubated in vitro with insoluble LDL-containing immune complexes accumulate cholesterol and are transformed into foam cells.

It should be mentioned that the LDL of immune complexes amounts to not more than 2% of the total circulating LDL pool [4, 5]. However, this LDL fraction is fundamental to the serum atherogenicity manifested at the cellular level. In a cell culture, immune complexes isolated from the serum cause atherosclerosis-related changes similar to those caused by the whole serum [4, 5]. There is a direct correlation between the LDL content of circulating immune complexes and serum atherogenic potential [4].

Orekhov et al. [44] have shown that insoluble immune complexes containing LDL and heterologous anti-LDL antibodies induce lipid accumulation in cultured cells. The ability of antibodies to stimulate lipid accumulation was found to be dependent on the LDL content of the immune complex [44]. It was also shown that the atherogenic potential of desialylated LDL isolated from the blood of atherosclerotic patients is markedly increased if the LDL forms an immune complex with autoantibodies [2]. The addition of desialylated LDL and anti-LDL autoantibodies to cultured human aortic smooth muscle cells enhanced the intracellular cholesterol accumulation considerably [2, 45, 46]. Native LDL that did not induce intracellular cholesterol accumulation became atherogenic after interaction with autoantibodies (i.e., the LDL acquires the ability to increase the cholesterol content of cultured cells) [2, 45, 46]. Interaction of LDL with anti-LDL autoantibodies considerably increases the uptake (binding and internalization) of the lipoprotein by arterial cells, which may account for the stimulating effect of antibodies on the LDL-induced accumulation of intracellular cholesterol [2]. After being added to a cell culture together with antibodies, fibronectin and C1q complement component (which are the constituents of an immune complex) increase the LDL uptake to a greater extent than the antibodies added alone. This leads to a massive cholesterol accumulation [2].

It was demonstrated that removal of IgG and IgM as well as circulating immune complexes from atherogenic sera of CHD patients leads to a partial or complete elimination of their atherogenic properties (i.e., its ability to induce intracellular lipid accumulation). Removal of immunoglobulin G caused the greatest fall in the serum atherogenicity; the fall was lower after removal of immunoglobulin M, and atherogenicity remained virtually unchanged after immunoglobulin A removal [3]. These facts lead to the suggestion that the majority of the atherogenic LDL of an immune complex is bound with antibodies of the immunoglobulin G class; there is no evidence that IgG-containing LDL-CIC may be more atherogenic and those results only allow assuming that just IgG and, in lesser extent, IgM but not IgA participate in LDL-CIC formation. At the same time, circulating immune complexes (CIC) isolated from these sera brought about accumulation of cholesterol in cultured SMC of unaffected human aortic intima. The ability of atherogenic sera to stimulate the accumulation of intracellular cholesterol correlated with the cholesterol level in the CIC isolated from these sera. The cholesterol content in CIC isolated from sera of CHD patients, which displayed atherogenic properties in culture, was characterized by an elevated cholesterol level in CIC (33.2 ± 1.2 pg/mL) significantly (P < 0.01) different from the values seen in the group of healthy donors. Neither of the nonatherogenic sera had an elevated CIC-cholesterol level. These findings suggest that in most cases the cholesterol-containing immune complexes are responsible for the atherogenic properties of the serum [3]. Basing on the knowledge of the absence of atherogenicity of native LDL, it can be suggested that nonmodified LDL does not produce an immune response, and for the formation of LDL-CIC lipoprotein particles should be modified in some way; apo-B desialylation may act as one of the mechanisms of LDL immunogenic modification. At the same time, it is unknown whether LDL-CIC contain only modified LDL, or also native LDL; the last is possible due to common immunoglobulin-binding sites, which may be present in both native and modified LDL.

The mechanisms of intracellular lipid accumulation caused by LDL-CIC obviously are an area that needs further investigation. There is evidence that immune complexes formed between modified LDL as antigens and IgG autoantibodies may modulate the inflammation in atherosclerosis via Fc receptor signaling and complement activation; the role of antibody isotypes in atherogenesis is unclear, since IgG is regarded as potentially proatherogenic, and IgM may even play a protective role [47]. The last finding contradicts with earlier data on atherogenicity of IgM-containing LDL-CIC; however, till now there is no evidence that activation of inflammation and foam cells formation should go in parallel. It is not definitely known in which way foam cells formed as a result of intracellular lipid accumulation further drive the progression of atherosclerosis; there exists the possibility of macrophages to acquire proinflammatory phenotype after ingesting LDL-IgG through Fc gamma receptor. However, it is known that LDL-CIC may induce other atherosclerosis-related processes at the cellular level, namely, excessive production of connective tissue matrix and cellular proliferation [5, 36]. It has been shown recently that in vitro produced immune complexes containing oxidized LDL stimulate type IV collagen production by mesangial cells, the effect being realized via Fc gamma receptors I and III [48]. Such immune complexes also increased proliferative activity of cultured human monocytes, and this effect was mediated by cross-linking of Fc gamma receptor I; a concentration-dependent production of monocyte colony-stimulating factor was observed. These results offered a novel mechanism by which an immune reaction toward
modified LDL can play a role in local accumulation of macrophages in atherosclerotic lesions [49]. It is generally approved that LDL-CIC effects are mediated via interaction of immunoglobulin moiety with Fc receptors; since IgG and IgM antibodies do not share the same receptors, this may be the explanation for the abovementioned difference in uptake of LDL bound either to IgG or to IgM.

It has been demonstrated that the lipoprotein-antibody complexes prepared in vitro affect lipoprotein metabolism in human fibroblasts and monocytes [50, 51] and facilitate the accumulation of lipids in mouse macrophages [52]. Complexes of human LDL with polyclonal goat antibodies against LDL induce the deposition of lipids in cultured SMC of human aortic intima and peritoneal mouse macrophages [3].

Taken together, these findings suggest that multiple-modified desialylated LDL has immunogenic properties and circulating immune complexes containing modified LDL and anti-LDL autoantibodies are the blood components responsible for primary cholesterol accumulation in vascular cells. Since cholesterol accumulation is accompanied by stimulation of other atherosclerotic manifestations at the cellular level, it can be suggested that the presence of LDL-containing complexes in the blood promotes the emergence and development of atherosclerotic lesions in the vessel wall.

4. Diagnostic and Prognostic Value of LDL-CIC in Atherosclerosis

Using a simple method of measurement of LDL-CIC level, Orekhov et al. demonstrated that only LDL-CIC level and the apo B/apo A-1 ratio contributed strongly to the discrimination between patients with coronary and/or extracorony atherosclerosis and those without stenosis [53]. In the same study, total cholesterol, triglycerides, HDL cholesterol, apo B, Lp[a], and apo AI did not correlate with the presence and severity of coronary and/or extracorony atherosclerosis. The authors concluded that LDL-CIC level might be the most reliable marker of atherosclerosis as compared to other parameters of lipid profile. LDL-CIC level was significantly correlated also with the severity of coronary atherosclerosis, and this biochemical parameter was proposed to be used as a sensitive and specific marker for atherosclerosis, possessing a high diagnostic value [5, 53, 54]. Salonen et al. have reported that the titer of antibodies against MDA-modified LDL in blood serum is associated with the progression of a carotid atherosclerosis [55]. In the recent Epidemiology of Diabetes Interventions and Complications (EDIC) Trial it has been demonstrated that cholesterol and apolipoprotein B content of immune complexes were significantly higher in patients who showed progression of the internal carotid IMT than in those showing no progression, regression, or mild progression, and cholesterol content of immune complexes was a significant positive predictor of internal carotid IMT progression [56]. High cholesterol levels in CIC are considered to be surrogate markers of modified LDL associated with increased carotid intima-media thickness and cardiovascular events. Lopes-Virella et al. have measured oxidized LDL, advanced glycation end products-modified LDL, and malondialdehyde-modified LDL in CIC, determined their relationship with increased carotid IMT in type I diabetes, and compared the strength of the association with that observed with conventional risk factors [57].

The most recent evaluation of diagnostic and predictive role of LDL-CIC (immune cholesterol) as well as other lipid parameters in early carotid atherosclerosis was carried out by Sobenin at al. in two-year prospective study [58]. The rate of atherosclerosis progression was estimated by high-resolution B-mode ultrasonography as the increase in intima-media thickness (IMT) of common carotid arteries. The patients with elevated levels of LDL-CIC were characterized by significantly higher levels of serum total and LDL cholesterol as well as significantly increased mean and maximum intima-media thickness of common carotid arteries. Cholesterol level of LDL-CIC and serum LDL cholesterol were contingent with the extent of early carotid atherosclerosis (P = 0.042 and P = 0.049, resp.). Additionally, LDL-CIC was characterized by the highest values of sensitivity and specificity as compared to commonly used lipid parameters. Only LDL-CIC, but not any other lipid parameter, was contingent with the progression of early carotid atherosclerosis (P = 0.042) and also had the highest levels of relative risk and odds ratio [59]. Normal level of LDL-CIC (below 16.0 μg/ml) was the only parameter that predicted the absence of carotid atherosclerosis progression for two following years at prognostic value of 78.3% (95% CI, 67.1–87.3) [59]. Normal levels of serum total cholesterol, LDL and HDL cholesterol, and triglycerides did not possess statistically significant predictive values. Thus, in spite of the absence of clinical manifestations of atherosclerosis, the elevated level of LDL-CIC is associated with increased intima-media thickness and can be regarded as a predictor for higher risk of atherosclerosis development [58, 59].

In large meta-analyses of prospective population studies in 165,544 participants without baseline CVD in 37 prospective cohorts (calendar years of recruitment: 1968–2007) with up to 15,126 incident fatal or nonfatal CVD outcomes (10,132 CHD and 4994 stroke outcomes) during a median follow-up of 10.4 years (interquartile range: 7.6–14 years), both baseline LDL and HDL cholesterol levels were strong predictors of both CHD and stroke [60]. The studies included in this cited meta-analysis described conventional lipid profile parameters, but not LDL-CIC, as predicting variables. However, the results of analysis demonstrate that the predictive biomarkers in healthy population are not the same as those for the diagnosis and prognosis of atherosclerosis; therefore, diagnostic and prognostic role of LDL-CIC should be in focus for further investigations in both nonatherosclerotic subjects and preclinical and overt atherosclerosis.

5. Conclusions

On the basis of current data, it is possible to define the role of lipoprotein-containing immune complexes in atherogenesis (Figure I). It can be supposed that LDL-CIC may play a significant role in atherogenesis and are involved in the formation of early atherosclerotic lesion. LDL-CIC can induce massive cholesterol accumulation in cultured vascular cells
Regarding the publication of this paper, the authors declare that there is no conflict of interests.

Acknowledgments

This work was supported by the Russian Scientific Foundation (Grant 14-15-00112) and by TEKES, Finland. The authors also wish to acknowledge the support from the School of Medical Sciences, University of New South Wales, Sydney, Australia.

References

[1] V. V. Tertov, A. N. Orekhov, L. H. Ryong, and V. N. Smirnov, “Intracellular cholesterol accumulation is accompanied by enhanced proliferative activity of human aortic intimal cells,” Tissue and Cell, vol. 20, no. 6, pp. 849–854, 1988.
[2] A. N. Orekhov, V. V. Tertov, S. A. Kudryashov, and V. N. Smirnov, “Triggerlike stimulation of cholesterol accumulation and DNA and extracellular matrix synthesis induced by atherogenic serum or low density lipoprotein in cultured cells,” Circulation Research, vol. 66, no. 2, pp. 311–320, 1990.
[3] P. Libby, P. M. Ridker, and G. K. Hansson, “Progress and challenges in translating the biology of atherosclerosis,” Nature, vol. 473, no. 7347, pp. 317–325, 2011.
[4] V. V. Tertov, A. N. Orekhov, K. S. Sayadyan et al., “Correlation between cholesterol content in circulating immune complexes and atherogenic properties of CHD patients’ serum manifested in cell culture,” Atherosclerosis, vol. 81, no. 3, pp. 183–189, 1990.
[5] V. V. Tertov, A. N. Orekhov, A. G. Kacharava, I. A. Sobenin, N. V. Perova, and V. N. Smirnov, “Low density lipoprotein-containing circulating immune complexes and coronary atherosclerosis,” Experimental and Molecular Pathology, vol. 52, no. 3, pp. 300–308, 1990.
[6] C. Gisinger, G. T. Virella, and M. F. Lopes-Virella, “Erythrocyte-bound low-density lipoprotein immune complexes lead to cholesterol ester accumulation in human monocyte-derived macrophages,” Clinical Immunology and Immunopathology, vol. 59, no. 1, pp. 37–52, 1991.
[7] A. G. Kacharava, V. V. Tertov, and A. N. Orekhov, “Autoantibodies against low density lipoprotein and atherogenic potential of blood,” Annales of Medicine, vol. 25, no. 6, pp. 551–555, 1993.
[8] G. Virella, M. F. Lopes-Virella, C. J. Binder, and J. L. Witzum, “Humoral immunity and atherosclerosis,” Nature Medicine, vol. 9, no. 3, pp. 243–245, 2003.
[9] M. F. Lopes-Virella, N. Binzafar, S. Rackley, A. Takei, M. La Via, and G. Virella, “The uptake of LDL-IC by human macrophages: predominant involvement of the FcγRI receptor,” Atherosclerosis, vol. 135, no. 2, pp. 161–170, 1997.
[10] J. L. Beaumont, “Hyperlipidemia with circulating anti-beta-lipoprotein auto-antibody in man. Auto-Immune hyperlipidemia, its possible role in atherosclerosis,” Progress in Biochemical Pharmacology, vol. 4, pp. 110–121, 1968.
[11] J. L. Beaumont, “Hyperlipidemia par auto-anticorps anti-beta-lipoproteine. Une nouvelle entite pathologique,” Comptes Rendus Hebdomadaires des Seances de l Academie des Sciences D, vol. 261, pp. 4563–4566, 1965.
[12] E. Szondy, M. Horváth, Z. Mezei et al., “Free and complexed anti-lipoprotein antibodies in vascular diseases,” Atherosclerosis, vol. 49, no. 1, pp. 69–77, 1983.
[13] B. J. Bauer, K. Blashfield, R. Norris, D. A. Buthala, and L. C. Ginsberg, “Immunoglobulin as the major low density lipoprotein binding protein in plasma,” Atherosclerosis, vol. 44, no. 2, pp. 153–160, 1982.

Abbreviations

CHD: Coronary heart disease
CIC: Circulating immune complexes
HDL: High density lipoprotein
LDL: Low density lipoprotein
LDL-CIC: LDL-containing circulating immune complexes
MDA: Malondialdehyde
SMC: Smooth muscle cells
IMT: Intima-media thickness

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Figure 1: Schematic presentation of the role of lipoprotein-containing immune complexes in atherosclerosis.
[14] U. P. Steinbrecher, M. Fisher, J. L. Witztum, and L. K. Curtiss, “Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: generation of antibodies specific for derivatized lysine,” Journal of Lipid Research, vol. 25, no. 10, pp. 1109–1116, 1984.

[15] J. L. Witztum, U. P. Steinbrecher, Y. A. Kesaniemi, and M. Fisher, “Autoantibodies to glucosylated proteins in the plasma of patients with diabetes mellitus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 81, no. 10, pp. 3204–3208, 1984.

[16] W. Palinski, M. E. Rosenfeld, S. Yla-Herttuala et al., “Low density lipoprotein undergoes oxidative modification in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 4, pp. 1372–1376, 1989.

[17] V. Pollak, “Plasma apolipoproteins AI, lipoprotein A and nonatherosclerotic rabbits,” Atherosclerosis, vol. 34, no. 4, pp. 391–405, 1979.

[18] G. K. Hansson, G. Bondjers, A. Bylock, and H. Ljhalmarsson, "Ultrastructural studies on the localization of IgG in the aortic endothelium and subendothelial intima of atherosclerotic and nonatherosclerotic rabbits," Experimental and Molecular Pathology, vol. 33, no. 3, pp. 302–315, 1980.

[19] D. Parums and M. J. Mitchinson, “Demonstration of immunoglobulin in the neighbourhood of advanced atherosclerotic plaques,” Atherosclerosis, vol. 38, no. 1-2, pp. 211–216, 1981.

[20] L. A. Lewis and I. H. Page, “An unusual serum lipoprotein-globulin complex in a patient with hyperlipemia,” The American Journal of Medicine, vol. 38, no. 2, pp. 286–297, 1965.

[21] D. J. Beutler, “Autoimmune hyperlipidemia,” in Atherosclerosis (Proceedings of the 2nd International Symposium), R. G. Jones, Ed., Springer, Berlin, Germany, 1970.

[22] G. Noseda, W. Riesen, E. Schlumpf, and A. Morell, “Hypoa-lipoproteinaemia associated with auto-antibodies against-lipoproteins,” European Journal of Clinical Investigation, vol. 2, no. 5, pp. 342–347, 1972.

[23] A. A. Klimov, A. D. Denisenko, N. Zubzhitsky Yu., and E. A. Gerchikova, “Detection of autoimmune complex lipoprotein-antibody in human blood plasma and aorta wall,” Voprosy Meditsinskoy Khimii, vol. 24, no. 4, pp. 539–543, 1978 (Russian).

[24] A. N. Orekhov, “Lipoprotein immune complexes and their role in atherogenesis,” Current Opinion in Lipidology, vol. 2, no. 5, pp. 329–333, 1991.

[25] J. T. Salonen, “Markers of oxidative damage and antioxidant protection: assessment of LDL oxidation,” Free Radical Research, vol. 33, pp. S41–S46, 2000.

[26] P. Avogaro, G. B. Bon, and G. Gazzolato, “Presence of a modified low density lipoprotein in humans,” Arteriosclerosis, vol. 8, no. 1, pp. 79–87, 1988.

[27] L. K. Curtiss and J. L. Witztum, “Plasma apolipoproteins AI, all, B, and E are glucosylated in hyperglycemic diabetic subjects,” Diabetologia, vol. 34, no. 5, pp. 452–461, 1995.

[28] A. N. Orekhov, V. V. Tertov, D. N. Mukhin, and I. A. Mikhailenko, “Modification of low density lipoprotein by desialylation causes lipid accumulation in cultured cells: discovery of desialylated lipoprotein with altered cellular metabolism in the blood of atherosclerotic patients,” Biochemical and Biophysical Research Communications, vol. 162, no. 1, pp. 206–211, 1989.

[29] U. Mutlu-Türkoğlu, Z. Akalin, E. Ilhan et al., “Increased plasma malondialdehyde and protein carbonyl levels and lymphocyte DNA damage in patients with angiographically defined coronary artery disease,” Clinical Biochemistry, vol. 38, no. 12, pp. 1059–1065, 2005.

[30] Z. J. Zhang, “Systematic review on the association between F2-isoprostanes and cardiovascular disease,” Annals of Clinical Biochemistry, vol. 50, part 2, pp. 108–114, 2013.

[31] B. Shao and J. W. Heinecke, “HDL, lipid peroxidation, and atherosclerosis,” Journal of Lipid Research, vol. 50, no. 4, pp. 599–601, 2009.

[32] T. J. Lyons, R. L. Klein, J. W. Baynes, H. C. Stevenson, and M. F. Lopes-Virella, “Stimulation of cholesteryl ester synthesis in human monocyte-derived macrophages by low-density lipoproteins from Type I (insulin-dependent) diabetic patients: the influence of non-enzymatic glycosylation of low-density lipoproteins,” Diabetologia, vol. 30, no. 12, pp. 916–923, 1987.

[33] M. F. Lopes-Virella, R. L. Klein, T. J. Lyons, H. C. Stevenson, and J. L. Witztum, “Glycosylation of low-density lipoprotein enhances cholesteryl ester synthesis in human monocytederived macrophages,” Diabetes, vol. 37, no. 5, pp. 550–557, 1988.

[34] V. V. Tertov, I. A. Sobenin, A. G. Tonevitsky, A. N. Orekhov, and V. N. Smirnov, “Isolation of atherogenic modified (desialylated) low density lipoprotein from blood of atherosclerotic patients: separation from native lipoprotein by affinity chromatography,” Biochemical and Biophysical Research Communications, vol. 167, no. 3, pp. 1122–1127, 1990.

[35] A. N. Klimov, A. D. Denisenko, A. G. Vinogradov et al., “Accumulation of cholesteryl esters in macrophages incubated with human lipoprotein-antibody autoimmune complex,” Atherosclerosis, vol. 74, no. 1-2, pp. 41–46, 1988.

[36] V. V. Tertov, I. A. Sobenin, A. N. Orekhov, O. Jaakkola, T. Solakivi, and T. Nikkari, “Characteristics of low density lipoprotein isolated from circulating immune complexes,” Atherosclerosis, vol. 122, no. 2, pp. 191–199, 1996.

[37] A. N. Orekhov, V. V. Tertov, and D. N. Mukhin, “Desialylated low density lipoprotein—naturally occurring modified lipoprotein with atherogenic potency,” Atherosclerosis, vol. 86, no. 2-3, pp. 153–161, 1991.

[38] V. V. Tertov, A. N. Orekhov, I. A. Sobenin, J. D. Morriset, A. M. Gotto Jr., and J. G. Guevara Jr., “Carbohydrate composition of protein and lipid components in sialic acid-rich and -poor low density lipoproteins from subjects with and without coronary artery disease,” Journal of Lipid Research, vol. 34, no. 3, pp. 365–375, 1993.

[39] V. V. Tertov, I. A. Sobenin, Z. A. Gabbasov et al., “Multiple-modified desialylated low density lipoproteins that cause intracellular lipid accumulation: isoformation and characterization,” Laboratory Investigation, vol. 67, no. 5, pp. 665–675, 1992.

[40] A. N. Orekhov, V. V. Tertov, A. E. Kabakov, I. Y. Adamova, S. N. Pokrovsky, and V. N. Smirnov, “Autoantibodies against modified low density lipoprotein. Nonlipid factor of blood plasma that stimulates foam cell formation,” Arteriosclerosis and Thrombosis, vol. 11, no. 2, pp. 316–326, 1991.

[41] C. Dachet, M. F. Baudet, and J. L. Beaumont, “Cholesterol synthesis by human fibroblasts in the presence of LDL and anti-LDL IgA,” Biomedicine, vol. 31, no. 3, pp. 80–82, 1979.

[42] A. N. Klimov, A. D. Denisenko, A. V. Popov et al., “Lipoprotein-antibody immune complexes their catabolism and role in foam cell formation,” Atherosclerosis, vol. 58, no. 1–3, pp. 1–15, 1985.

[43] R. L. Griffith, G. T. Virella, H. C. Stevenson, and M. F. Lopes-Virella, “Low density lipoprotein metabolism by human...
macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation,” *Journal of Experimental Medicine*, vol. 168, no. 3, pp. 1041–1059, 1988.

[44] A. N. Orekhov, V. V. Tertov, D. N. Mukhin et al., “Insolubilization of low density lipoprotein induces cholesterol accumulation in cultured subendothelial cells of human aorta,” *Atherosclerosis*, vol. 79, no. 1, pp. 59–70, 1989.

[45] A. N. Orekhov and V. V. Tertov, “Antibody-like immunoglobulins G against low density lipoprotein that stimulate lipid accumulation in cultured cells,” *Advances in Experimental Medicine and Biology*, vol. 285, pp. 399–405, 1991.

[46] A. N. Orekhov and V. V. Tertov, “Atherogenicity of autoantibodies against low density lipoprotein,” *Agents and Actions*, vol. 32, no. 1-2, pp. 128–129, 1991.

[47] D. F. Burut, Y. Karim, and G. A. A. Ferns, “The role of immune complexes in atherogenesis,” *Angiology*, vol. 61, no. 7, pp. 679–689, 2010.

[48] S. A. Abdelsamie, Y. Li, Y. Huang et al., “Oxidized LDL immune complexes stimulate collagen IV production in mesangial cells via Fc gamma receptors I and III,” *Clinical Immunology*, vol. 139, no. 3, pp. 258–266, 2011.

[49] R. Oksjoki, P. T. Kovanen, K. A. Lindstedt, B. Jansson, and M. O. Pentik¨ainen, “OxLDL-IgG immune complexes induce survival of human monocytes,” *Atherosclerosis, Thrombosis, and Vascular Biology*, vol. 26, no. 3, pp. 576–583, 2006.

[50] M.-F. Baudet, C. Dachet, and J. L. Beaumont, “Interaction between fibroblasts, lipoproteins and three antilipoproteins IgA kappa,” *Clinical and Experimental Immunology*, vol. 39, no. 2, pp. 455–460, 1980.

[51] M. J. Tikkanen, R. Dargar, B. Pfleger, B. Gonen, J. M. Davie, and G. Schonfeld, “Antigenic mapping of human low density lipoprotein with monoclonal antibodies,” *Journal of Lipid Research*, vol. 23, no. 7, pp. 1032–1038, 1982.

[52] A. N. Klimov, A. D. Denisenko, A. V. Popov et al., “Lipoprotein-antibody immune complexes their catabolism and role in foam cell formation,” *Atherosclerosis*, vol. 58, no. 1–3, pp. 1–15, 1985.

[53] A. N. Orekhov, O. S. Kalenich, V. V. Tertov, and I. D. Novikov, “Lipoprotein immune complexes as markers of atherosclerosis,” *International Journal of Tissue Reactions*, vol. 13, no. 5, pp. 233–236, 1991.

[54] A. N. Orekhov, O. S. Kalenich, V. V. Tertov et al., “Diagnostic value of immune cholesterol as a marker for atherosclerosis,” *Journal of Cardiovascular Risk*, vol. 2, no. 5, pp. 459–466, 1995.

[55] J. T. Salonen, S. Yl¨a-Herttuala, R. Yamamoto et al., “Autoantibody against oxidised LDL and progression of carotid immunoglobulin,” *The Lancet*, vol. 339, no. 8798, pp. 883–887, 1992.

[56] M. F. Lopes-Virella, M. B. McHenry, S. Lipsitz et al., “Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes,” *Atherosclerosis*, vol. 190, no. 2, pp. 359–369, 2007.

[57] M. F. Lopes-Virella, K. J. Hunt, N. L. Baker, J. Lachin, D. M. Nathan, and G. Virella, “Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes,” *Diabetes*, vol. 60, no. 2, pp. 582–589, 2011.

[58] I. A. Sobenin, V. P. Karagodin, A. A. Melnichenko, Y. V. Bobryshev, and A. N. Orekhov, “Diagnostic and prognostic value of low density lipoprotein-containing circulating immune complexes in atherosclerosis,” *Journal of Clinical Immunology*, vol. 33, no. 2, pp. 489–495, 2013.

[59] I. A. Sobenin, V. A. Orekhova, A. A. Melnichenko, Y. V. Bobryshev, and A. N. Orekhov, “Low density lipoprotein-containing circulating immune complexes have better prognostic value in carotid intima-media thickness progression than other lipid parameters,” *International Journal of Cardiology*, vol. 166, no. 3, pp. 747–748, 2013.

[60] E. Di Angelantonio, P. Gao, L. Pennells et al., “Lipid-related markers and cardiovascular disease prediction,” *Journal of the American Medical Association*, vol. 307, no. 23, pp. 2499–2506, 2012.